Inhibikase Therapeutics (IKT) vs Palisade Bio (PALI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Inhibikase Therapeutics (IKT) has outperformed Palisade Bio (PALI) over the past year, gaining 15.1% versus a loss of 27.5%. Over five years, IKT leads with a -83.5% price change compared with -99.9% for PALI. Inhibikase Therapeutics is the larger company by market cap ($266.5 million vs $252.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IKT | PALI |
|---|---|---|
| Share price | $1.91 | $1.45 |
| Market cap | $266.51M | $252.69M |
| 1-day change | -1.55% | -2.03% |
| YTD return | -6.83% | -38.30% |
| 1-year return | +15.06% | -27.50% |
| 5-year return | -83.51% | -99.93% |
| P/E ratio (TTM) | — | 2.42 |
| EPS (TTM) | $-0.43 | $0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.61 | $2.86 |
| 52-week low | $1.33 | $1.32 |
| Distance from 52-week high | -26.82% | -49.30% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +214.14% | +604.83% |
| Average volume | 652.84K | 2.56M |
| Shares outstanding | 139.54M | 174.27M |
| Employees | 35 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IKT has outperformed PALI by 42.6 percentage points over the past year.
About Inhibikase Therapeutics
IKT stock →Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
About Palisade Bio
PALI stock →Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
IKT vs PALI FAQ
Which is bigger, Inhibikase Therapeutics or Palisade Bio?
Inhibikase Therapeutics (IKT) is larger, with a market capitalization of $266.51M compared with $252.69M for Palisade Bio (PALI).
Which stock has performed better over the past year, IKT or PALI?
IKT returned +15.06% over the past 12 months, compared with -27.50% for PALI (price return, excluding dividends). Past performance does not predict future results.
Are Inhibikase Therapeutics and Palisade Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.